Related Experiment Video

Updated: Jul 27, 2026

Spheroid Assay to Measure TGF-β-induced Invasion
09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

[A study on the inhibiting effects of transforming growth factor-beta R II antibody on fibroblasts]

Yu-zhu Quan1, Hong-xing Zhuang, Qing-guo Zhang

  • 1Plastic Surgery Hospital of Chinese Academy of Medical Sciences, Beijing 100041, China.

Zhonghua Zheng Xing Wai Ke Za Zhi = Zhonghua Zhengxing Waike Zazhi = Chinese Journal of Plastic Surgery
|June 8, 2004
PubMed
Abstract

Insights

Transforming growth factor-beta type R II receptor (TGF-beta R II) antibody significantly inhibits fibroblast proliferation. This effect is dose-dependent, indicating its potential as a therapeutic agent.

Area of Science:

  • Cell biology
  • Immunology
  • Dermatology

Background:

  • Fibroblasts play a crucial role in tissue repair and remodeling.
  • Transforming growth factor-beta (TGF-beta) signaling is implicated in various fibrotic diseases.
  • Targeting TGF-beta signaling pathways is a potential therapeutic strategy.

Purpose of the Study:

  • To investigate the inhibitory effects of a transforming growth factor-beta type R II receptor (TGF-beta R II) antibody on fibroblast proliferation.
  • To determine the dose-dependent relationship of this inhibition.

Main Methods:

  • Cultured human skin fibroblasts were divided into four groups.
  • Treatment with varying dosages of TGF-beta R II antibody.
  • Analysis using hydroxyproline (HYP) assay, MTT assay, microscopy, and flow cytometry.

Main Results:

  • TGF-beta R II antibody demonstrated significant inhibition of fibroblast proliferation (P < 0.01).
  • Microscopic examination and flow cytometry supported the observed antiproliferative effects.
  • Hydroxyproline and MTT assays quantified the reduction in fibroblast activity.

Conclusions:

  • TGF-beta R II antibody effectively inhibits skin fibroblast proliferation.
  • The inhibitory action is dose-dependent, suggesting a targeted therapeutic potential.
  • This antibody represents a promising candidate for modulating fibroblast activity in relevant conditions.

More Related Videos

Studying TGF-&#946; Signaling and TGF-&#946;-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Fibroblast Derived Human Engineered Connective Tissue for Screening Applications09:50

Fibroblast Derived Human Engineered Connective Tissue for Screening Applications

Published on: August 20, 2021

Related Concept Videos

Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
TGF - &#946; Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...